what is bronchitis
Info about bronchitis coughing => bronchitis cures => Topic started by: glennaguilar on August 18, 2016, 07:03:19 am
-
Bronchitis Cause Asthma - Fluoroquinolone Antibiotics Classification, Uses and Side Effects
The fluoroquinolones are a relatively new group of antibiotics. Fluoroquinolones were first introduced in 1986, but they are really modified quinolones, a class of antibiotics, whose accidental discovery occurred in the early 1960.
Fluoroquinolones Advantages:
Ease of administration Daily or twice daily dosing Excellent oral absorption Excellent tissue penetration Prolonged half-lives Significant entry into phagocytic cells Efficacy Overall safety We have written a humorous anecdote on Bronchitis to make it's reading more enjoyable and interesting to you. This way you learn there is a funny side to Bronchitis too!
Side Effects
The fluoroquinolones as a class are generally well tolerated. Most adverse effects are mild in severity, self-limited, and rarely result in treatment discontinuation. However, they can have serious adverse effects. We were furnished with so many points to include while writing about Bronchitis that we were actually lost as to which to use and which to discard!
Because of concern about hepatotoxicity, trovafloxacin therapy should be reserved for life- or limb-threatening infections requiring inpatient treatment (hospital or long-term care facility), and the drug should be taken for no longer than 14 days. It was at the spur of the moment that we ventured to write something about Bronchitis. Such is the amount of matter that is available on Bronchitis.
Second Generation
The second-generation fluoroquinolones have increased gram-negative activity, as well as some gram-positive and atypical pathogen coverage. Compared with first-generation quinolones, these drugs have broader clinical applications in the treatment of complicated urinary tract infections and pyelonephritis, sexually transmitted diseases, selected pneumonias and skin infections. The results of one reading this composition is a good understanding on the topic of Bronchitis. So do go ahead and read this to learn more about Bronchitis.
First Generation
The first-generation agents include cinoxacin and nalidixic acid, which are the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were used primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing than the newer quinolones, and they are more susceptible to the development of bacterial resistance. Writing an article on Bronchitis was our foremost priority while thinking of a topic to write on. This is because Bronchitis are interesting parts of our lives, and are needed by us.
(https://s3-us-west-2.amazonaws.com/979/imgs/USP-PedAntibiotic-T.jpeg)
Pediatric Antibiotic Use: a Focused Review of Fluoroquinolones and
The fluoroquinolones are a family of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of the group is nalidixic acid, discovered in 1962 by Lescher and colleagues. The first fluoroquinolones were widely used because they were the only orally administered agents available for the treatment of serious infections caused by gram-negative organisms, including Pseudomonas species. Remember that it is very important to have a disciplined mode of writing when writing. This is because it is difficult to complete something started if there is no discipline in writing especially when writing on Bronchitis.
Fluoroquinolones Disadvantages:
Tendonitis or tendon rupture Multiple drug interactions Not used in children Newer quinolones produce additional toxicities to the heart that were not found with the older agents Sometimes, what we hear about Chronic Bronchitis can prove to be rather hilarious and illogical. This is why we have introduced this side of Chronic Bronchitis to you. :o.
Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin is the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin are the most widely used second-generation quinolones because of their availability in oral and intravenous formulations and their broad set of FDA-labeled indications. It is only through sheer determination that we were able to complete this composition on Chronic Bronchitis. Determination, and regular time table for writing helps in writing essays, reports and articles. :o.
All of the fluoroquinolones are effective in treating urinary tract infections caused by susceptible organisms. They are the first-line treatment of acute uncomplicated cystitis in patients who cannot tolerate sulfonamides or TMP, who live in geographic areas with known resistance > 10% to 20% to TMP-SMX, or who have risk factors for such resistance. It is only because that we are rather fluent on the subject of Chronic Bronchitis that we have ventured on writing something so influential on Chronic Bronchitis like this!
Classification of Fluoroquinolones
As a group, the fluoroquinolones have excellent in vitro activity against a wide range of both gram-positive and gram-negative bacteria. The newest fluoroquinolones have enhanced activity against gram-positive bacteria with only a minimal decrease in activity against gram-negative bacteria. Their expanded gram-positive activity is especially important because it includes significant activity against Streptococcus pneumoniae. There is a lot of jargon connected with Chronic Bronchitis. However, we have eliminated the difficult ones, and only used the ones understood by everyone.
Fourth Generation
The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while maintaining the gram-positive and gram-negative activity of the third-generation drugs. They also retain activity against Pseudomonas species comparable to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan).
Because of their expanded antimicrobial spectrum, third-generation fluoroquinolones are useful in the treatment of community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis (http://freemanl6.phpbb.net/viewtopic.php?f=2&t=10), which are their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin.
The newer fluoroquinolones have a wider clinical use and a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Some of the newer fluoroquinolones have an important role in the treatment of community-acquired pneumonia and intra-abdominal infections.